Back
Compare AU
Compare CURE vs. HJHI
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Hejaz High Income Active ETF (HJHI). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | HJHI | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 66 | 4 |
Median incremental investment | $665.00 | $500.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,039.04 | $1,932.75 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | HJHI | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 41.75m in AUM and 146 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | HJHI.AX was created on 2024-05-02 by Hejaz . The fund's investment portfolio concentrates primarily on total market equity. To achieve a (total) return at least equal to movements in the Benchmark over a rolling 5 to 7-year timeframe through exposure to a diversified portfolio of Shariah Compliant listed companies with a proven history of significant dividends and a market capitalisation exceeding $2 billion. |
Top 3 holdings | Revolution Medicines Inc Ordinary Shares (1.70 %) Amicus Therapeutics Inc (1.49 %) Moderna Inc (1.44 %) | Moncler SpA (8.96 %) Okuma Corp (8.85 %) Merck & Co Inc (8.00 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Consumer Discretionary (43.19 %) Industrials (20.54 %) Materials (17.71 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 1.1 % |
Key Summary
CURE | HJHI | |
|---|---|---|
Issuer | Global X | Hejaz |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 1.1 % |
Price | $63.72 | $1.125 |
Size | $43.000 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 5.08 % | 1.85 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 29/04/2024 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | HJHI | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 66 | 4 |
Median incremental investment | $665.00 | $500.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,039.04 | $1,932.75 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | HJHI | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | HJHI |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |